Hanno B. Richards

6.7k total citations · 3 hit papers
58 papers, 5.0k citations indexed

About

Hanno B. Richards is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Hanno B. Richards has authored 58 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Rheumatology, 40 papers in Immunology and 16 papers in Hematology. Recurrent topics in Hanno B. Richards's work include Spondyloarthritis Studies and Treatments (26 papers), Psoriasis: Treatment and Pathogenesis (24 papers) and Systemic Lupus Erythematosus Research (21 papers). Hanno B. Richards is often cited by papers focused on Spondyloarthritis Studies and Treatments (26 papers), Psoriasis: Treatment and Pathogenesis (24 papers) and Systemic Lupus Erythematosus Research (21 papers). Hanno B. Richards collaborates with scholars based in United States, Switzerland and United Kingdom. Hanno B. Richards's co-authors include Shephard Mpofu, Westley H. Reeves, Brian Porter, Désirée van der Heijde, Minoru Satoh, Luminita Pricop, Iain B. McInnes, Jürgen Braun, Joachim Sieper and Philip J. Mease and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Hanno B. Richards

56 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

2015 732 citations Dominique Baeten, Joachim Sieper et al. profile →
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 650 citations Iain B. McInnes, Philip J. Mease et al. profile →
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

2015 572 citations Philip J. Mease, Iain B. McInnes et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hanno B. Richards United States	35	3.5k	3.4k	1.5k	544	411	58	5.0k
Sudha Visvanathan United States	35	2.5k 0.7×	3.5k 1.0×	1.7k 1.1×	394 0.7×	517 1.3×	71	5.4k
J. Wollenhaupt Germany	28	2.3k 0.7×	4.1k 1.2×	2.1k 1.4×	244 0.4×	327 0.8×	124	5.2k
Luminita Pricop United States	30	3.5k 1.0×	2.7k 0.8×	1.6k 1.1×	531 1.0×	531 1.3×	115	4.7k
Daniel Burge United States	14	1.6k 0.5×	2.6k 0.8×	1.5k 1.0×	305 0.6×	355 0.9×	23	3.9k
Frank Behrens Germany	27	2.4k 0.7×	2.5k 0.7×	1.4k 0.9×	235 0.4×	464 1.1×	178	3.7k
Shephard Mpofu United States	24	2.9k 0.8×	2.9k 0.8×	1.8k 1.2×	252 0.5×	520 1.3×	68	4.1k
Aileen L. Pangan United States	35	2.0k 0.6×	4.0k 1.2×	2.0k 1.4×	221 0.4×	722 1.8×	94	5.4k
John J. Cush United States	31	1.6k 0.5×	2.5k 0.7×	1.2k 0.8×	529 1.0×	100 0.2×	59	4.3k
Barbara Finck United States	8	1.3k 0.4×	2.7k 0.8×	1.5k 1.1×	268 0.5×	184 0.4×	17	3.6k
Andrea Rubbert‐Roth Germany	33	1.7k 0.5×	3.3k 1.0×	1.5k 1.0×	480 0.9×	93 0.2×	123	5.1k

Countries citing papers authored by Hanno B. Richards

Since Specialization

Citations

This map shows the geographic impact of Hanno B. Richards's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanno B. Richards with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanno B. Richards more than expected).

Fields of papers citing papers by Hanno B. Richards

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanno B. Richards. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanno B. Richards. The network helps show where Hanno B. Richards may publish in the future.

Co-authorship network of co-authors of Hanno B. Richards

This figure shows the co-authorship network connecting the top 25 collaborators of Hanno B. Richards. A scholar is included among the top collaborators of Hanno B. Richards based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanno B. Richards. Hanno B. Richards is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deodhar, Atul, Jerzy Supronik, Alan Kivitz, et al.. (2024). Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study. Arthritis & Rheumatology. 77(2). 163–170. 1 indexed citations

Gottlieb, Alice B., Atul Deodhar, Iain B. McInnes, et al.. (2022). Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Acta Dermato Venereologica. 102. adv00698–adv00698. 57 indexed citations

Marzo‐Ortega, Helena, Joachim Sieper, Alan Kivitz, et al.. (2020). 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. The Lancet Rheumatology. 2(6). e339–e346. 17 indexed citations

McInnes, Iain B., Dafna D. Gladman, Atul Deodhar, et al.. (2019). Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis. Queensland's institutional digital repository (The University of Queensland). 71. 1 indexed citations

Tahir, Hasan, Atul Deodhar, Mark C. Genovese, et al.. (2017). Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. Rheumatology and Therapy. 4(2). 475–488. 27 indexed citations

Heijde, Désirée van der, Robert Landewé, Philip J. Mease, et al.. (2016). Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis & Rheumatology. 68(8). 1914–1921. 61 indexed citations

Tłustochowicz, Witold, Proton Rahman, B. Seriolo, et al.. (2016). Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study. The Journal of Rheumatology. 43(3). 495–503. 32 indexed citations

Deodhar, Atul, Maxime Dougados, Dominique Baeten, et al.. (2016). Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). Arthritis & Rheumatology. 68(12). 2901–2910. 64 indexed citations

Gottlieb, Alice B., Philip Mease, Iain B. McInnes, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial. Queensland's institutional digital repository (The University of Queensland). 66. 12 indexed citations

10.

Mease, Philip, Iain B. McInnes, Bruce Kirkham, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Data Archiving and Networked Services (DANS). 66. 12 indexed citations

11.

Genovese, Mark C., Patrick Durez, Hanno B. Richards, et al.. (2014). One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. The Journal of Rheumatology. 41(3). 414–421. 83 indexed citations

12.

Yamasaki, Yoshioki, Sonali Narain, Hideo Yoshida, et al.. (2007). Autoantibodies to RNA helicase A: A new serologic marker of early lupus. Arthritis & Rheumatism. 56(2). 596–604. 34 indexed citations

13.

Yamasaki, Yoshioki, Sonali Narain, Tolga Barker, et al.. (2006). Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. Arthritis Research & Therapy. 8(4). R111–R111. 22 indexed citations

14.

Calvani, Nicola, Roberto Caricchio, Marco Tucci, et al.. (2005). Induction of Apoptosis by the Hydrocarbon Oil Pristane: Implications for Pristane-Induced Lupus. The Journal of Immunology. 175(7). 4777–4782. 63 indexed citations

15.

Zhuang, Haoyang, Sonali Narain, Eric S. Sobel, et al.. (2005). Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clinical Immunology. 117(3). 238–250. 62 indexed citations

16.

Calvani, Nicola, et al.. (2005). Th1 cytokines in the pathogenesis of lupus nephritis: The role of IL-18. Autoimmunity Reviews. 4(8). 542–548. 60 indexed citations

17.

Koç, Mehmet, Hanno B. Richards, Azra Bihorac, et al.. (2005). Circulating endothelial cells are associated with future vascular events in hemodialysis patients. Kidney International. 67(3). 1078–1083. 56 indexed citations

18.

Calvani, Nicola, Minoru Satoh, Byron P. Croker, Westley H. Reeves, & Hanno B. Richards. (2003). Nephritogenic autoantibodies but absence of nephritis in Il-12p35–deficient mice with pristane-induced lupus. Kidney International. 64(3). 897–905. 44 indexed citations

19.

Yoshida, Hideo, Minoru Satoh, Hanno B. Richards, et al.. (2002). Effect of an exogenous trigger on the pathogenesis of lupus in (NZB × NZW)F₁ mice. Arthritis & Rheumatism. 46(8). 2235–2244. 43 indexed citations

20.

Shaw, Melody, et al.. (2001). Increased prevalence of autoantibodies to Ku antigen in African American versus white patients with systemic lupus erythematosus. Arthritis & Rheumatism. 44(10). 2367–2370. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact